Page last updated: 2024-11-13

epi-isozizaene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

epi-isozizaene: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23724686
CHEBI ID51458
MeSH IDM0537183

Synonyms (11)

Synonym
(3s,3ar,6s)-3,7,7,8-tetramethyl-2,3,4,5,6,7-hexahydro-1h-3a,6-methanoazulene
CHEBI:51458
(1r,2s,8s)-2,6,7,7-tetramethyltricyclo[6.2.1.0(1,5)]undec-5-ene
(+)-epi-isozizaene
EL3 ,
LMPR0103700005
CYLSPJUZBPWJGC-PJRDJYAKSA-N
epi-isozizaene
2,2,3,7r-tetramethyl-1r,8s-tricyclo-[6.2.1.0(4,8)]undec-3-en
Q27122614
(1r,2s,8s)-2,6,7,7-tetramethyltricyclo[6.2.1.01,5]undec-5-ene
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sesquiterpeneA C15 terpene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
albaflavenone biosynthesis212

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's4 (44.44)24.3611
2020's4 (44.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]